TRANSDERM, INC.

Company Information
Address 2161 DELAWARE AVE
SANTA CRUZ, CA, 95060-5790


Information

DUNS: 557564775

# of Employees: N/A


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Novel topical delivery of botulinum A toxin to inhibit hyperhidrosis in inherited skin disorders.

    Amount: $224,655.00

    ABSTRACT The rare genetic disorder pachyonychia congenita PC results from dominant mutations in the inducible keratins K including K a K b K and K While disabling painful plantar keratoderm ...

    SBIRPhase I2016Department of Health and Human Services
  2. Development of topical formulations for delivery of next generation mTOR inhibito

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): We discovered that the inducible keratins 6a and 6b, mutations in which can result in the skin and nail disorder pachyonychia congenita (PC), contain regulatory mo ...

    SBIRPhase I2014Department of Health and Human Services
  3. Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAs

    Amount: $4,107,153.00

    DESCRIPTION (provided by applicant): RNA interference (RNAi) has the potential to revolutionize treatment of dominant genetic disorders. Small inhibitory RNAs (siRNAs) are highly potent and selective, ...

    SBIRPhase II2011Department of Health and Human Services
  4. Evaluation of siRNA uptake and functional activity in a human organotypic skin mo

    Amount: $340,859.00

    DESCRIPTION (provided by applicant): Although RNA interference offers high potential as a novel therapeutic approach for treating skin disorders, delivery concerns have hampered their progression to t ...

    SBIRPhase I2010Department of Health and Human Services
  5. Development of siRNA delivery methodologies using in vivo imaging models

    Amount: $1,380,800.00

    DESCRIPTION (provided by applicant): RNA interference offers the potential of a novel therapeutic approach for treating skin disorders. The ability to design, screen and identify potent, selective an ...

    SBIRPhase II2009Department of Health and Human Services
  6. Pachyonychia congenita clinical trial using therapeutic siRNAs

    Amount: $312,655.00

    DESCRIPTION (provided by applicant): ABSTRACT RNA interference (RNAi) has the potential to revolutionize treatment of dominant genetic disorders. Small inhibitory RNAs (siRNAs) are highly potent and s ...

    SBIRPhase I2008Department of Health and Human Services
  7. Development of topical rapamycin as a novel treatment for skin disorders

    Amount: $226,281.00

    DESCRIPTION (provided by applicant): In the decade and a half since the discovery of the underlying mutations in the keratin 5 (K5) and K14 genes in the skin disorder epidermolysis bullosa simplex (EB ...

    SBIRPhase I2008Department of Health and Human Services
  8. In vivo imaging models for evaluating siRNA delivery to skin

    Amount: $148,215.00

    DESCRIPTION (provided by applicant): RNA interference offers the potential of a novel therapeutic approach for treating skin disorders. The technology to design, screen and identify potent, selective ...

    SBIRPhase I2008Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government